Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062270 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00062270: Completed Phase 1 study, sponsored by University of Alabama at Birmingham.
NCT00062270 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00062270, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of the tumor. Combining chemotherapy and radiation therapy with gefitinib before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: Phase I/II trial to compare the effectiveness of neoadjuvant chemoradiotherapy with or without gefitinib in treating patients who are undergoing surgery for stage III non-small cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG docetaxel
- PROCEDURE conventional surgery
- DRUG gemcitabine hydrochloride
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-05 |
| Est. Completion | 2004-09 |
| Phase | Phase 1 |
What the finished NCT00062270 record still lists
NCT00062270 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00062270 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00062270 about?
NCT00062270 is a clinical study titled "Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of the ...
What is the current status of trial NCT00062270?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-05. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00062270?
The interventions under investigation include: cisplatin (DRUG), docetaxel (DRUG), conventional surgery (PROCEDURE), gemcitabine hydrochloride (DRUG), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00062270?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia